Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar

BACKGROUND: SB3, a biosimilar of Herceptin(®) (trastuzumab, hereinafter referred to as reference product) is currently approved in the EU, Korea, Australia, the USA, and Brazil for the treatment of human epidermal growth factor receptor (HER) 2-positive early and metastatic breast cancer and HER2-po...

Descripción completa

Detalles Bibliográficos
Autores principales: Paek, Kyungyeol, Kim, Go-woon, Ahn, So Yeong, Lim, Joon Hyuk, Jung, Dongkeum, Kim, Seokkyun, Lee, Jae Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875161/
https://www.ncbi.nlm.nih.gov/pubmed/31549311
http://dx.doi.org/10.1007/s40259-019-00381-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875161/
https://www.ncbi.nlm.nih.gov/pubmed/31549311
http://dx.doi.org/10.1007/s40259-019-00381-2

Ejemplares similares